All In Biotech

Drug Trial Radar · NCT06409936

PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Asciminib as Single Agent or in Combination With Nilotinib in the 1st-line Treatment of BCR-ABL1+ Chronic Myeloid Leukemia: a Randomized GIMEMA-GELMC Phase II Study PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CML

Last checked: Nov 20, 2026Latest source record: Jul 8, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 160 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

160

Planned (sponsor's estimate)

Start

Jun 26, 2025

Primary completion

Jun 2029

Study completion Jun 2032

Sponsor

Lead sponsor
Gruppo Italiano Malattie EMatologiche dell'AdultoAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Grupo Español de Leucemia Mieloide Crónica
First posted
May 10, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

A phase 2, interventional, randomized unblinded study will be conducted in newly diagnosed CP CML patients, to investigate the efficacy and the safety of asciminib at a dose of 80 mg QD as single agent (arm A) or 40 mg BID in combination with nilotinib 300 mg BID (arm B). All patients in both arm A and arm B will be treated for a minimum of 2 years (core phase). If they will have achieved a DMR (MR4), or if it will be in the interest of the patient, the treatment will be continued. During the consolidation phase (2 years) asciminib will be continued at the same dose in both arms; in the combination arm the nilotinib dose will be reduced to 300 mg daily. The patients maintaining a stable MR4 up to the end of the fourth year will discontinue the treatment (TFR phase). The rate of TFR at 5 year (1 year after discontinuation) will be evaluated.

Conditions

  • CML, Chronic Phase
  • Chronic Myeloid Leukemia, Chronic Phase
  • Chronic Myeloid Leukemia, BCR/ABL-Positive
  • Chronic Myeloid Leukemia

Interventions

  • AsciminibDrug

    both arms will include asciminib treatment

  • NilotinibDrug

    in the arm B the nilotinib will be added on in all patients

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. evaluation of response of asciminib single-agent or in combination with nilotinibTime frame: at 2 years

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Hospital del Mar (Barcelona)

    Barcelona, Spain · Recruiting

  • Hospital Universitario Basurto

    Bilbao, Spain · Recruiting

  • Institut Català d'Oncologia Girona

    Girona, Spain · Recruiting

  • Hospital Virgen de las Nieves

    Granada, Spain · Recruiting

  • Hospital Universitario de Gran Canaria Dr. Negrín

    Las Palmas de Gran Canaria, Spain · Recruiting

  • Hospital Gral U. Gregorio Marañón

    Madrid, Spain · Recruiting

  • Hospital Universitario 12 de Octubre

    Madrid, Spain · Recruiting

  • Hospital Universitario La Paz

    Madrid, Spain · Recruiting

  • Hospital Clínico Universitario Virgen de la Arrixaca

    Murcia, Spain · Recruiting

  • Complejo Asistencial Universitario de Salamanca

    Salamanca, Spain · Recruiting

  • Hospital Universitario La Fe Valencia

    Valencia, Spain · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.